Form 4: Jasper Therapeutics Director Receives Automatic Stock Option Grant

Jasper Therapeutics, Inc. Director Scott C. Brun was granted 7,500 stock options at an exercise price of $6.77, effective July 3, 2025, as part of the company's non-employee director compensation policy.

Summary

• Scott C. Brun, a Director of Jasper Therapeutics, Inc. (JSPR), was granted 7,500 stock options.
• The stock options have an exercise price of $6.77 per share.
• The grant date for these options was July 3, 2025.
• The options will become exercisable on July 3, 2026, and are set to expire on July 3, 2035.
• This grant was made automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides for an option to purchase 7,500 shares on the date of each annual meeting of stockholders.

Sentiment

Score: 6

Explanation: The filing reports a routine grant of stock options to a director as part of a pre-existing compensation policy, which is generally viewed as a neutral to slightly positive event as it aligns director incentives with shareholder interests without indicating any immediate operational or financial changes.

Positives

• The grant of stock options to Director Scott C. Brun aligns his interests with those of shareholders, incentivizing long-term company performance.
• The automatic nature of the grant under the Non-Employee Director Compensation Policy indicates a structured and transparent approach to director compensation.

Future Outlook

The stock options granted to Director Scott C. Brun will become exercisable on July 3, 2026, indicating a future vesting event that will allow for potential share acquisition.

Industry Context

The granting of stock options to non-employee directors is a common practice across various industries, particularly in biotechnology and growth-oriented companies, to attract and retain talent while aligning director incentives with shareholder value creation.

Comparison to Industry Standards

• The practice of granting stock options to non-employee directors is a standard compensation mechanism in the biotechnology sector, comparable to practices at companies like Regeneron Pharmaceuticals (REGN) or Amgen Inc. (AMGN) which also utilize equity-based incentives to align director interests with long-term company performance.
• The specific grant size of 7,500 shares is within typical ranges for directors at companies of similar market capitalization, though exact comparisons would require detailed analysis of peer group compensation policies and company-specific performance metrics.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align the director's financial interests with the long-term performance of the company, potentially benefiting shareholders through improved governance and strategic decisions.

Next Steps

• The stock options will become exercisable on July 3, 2026.
• The options will expire on July 3, 2035.

Key Dates

Keywords

Jasper Therapeutics, JSPR, Form 4, stock options, director compensation, beneficial ownership, SEC filing, equity grant